Roche - Top R&D innovators in med tech

Researcher in futuristic lab

2015 med tech R&D budget: $1.244 billion
Change from 2014 budget ($1.134 billion): 9%
Percent of 2015 segment sales ($11.24 billion): 10%

Roche ($RHHBY) relies on diagnostics to get its med tech engine running. This past year has included deals and product launches that help the company maintain dominance in a crowded field.

Roche recently got FDA approval for its liquid biopsy companion diagnostic for the cancer drug Tarceva. The news marked a big win for Roche, which faces a slew of competition in the liquid biopsy field.

But liquid biopsy is only part of Roche’s overall strategy. The company has also turned to dealmaking to ramp up R&D. In February 2015, Roche said it would shell out $1.2 billion for a majority share in Foundation Medicine ($FMI).

As part of the deal, Roche vowed to funnel $150 million over the next 5 years into a “broad R&D collaboration” with Foundation. The deal was meant to speed up product development and expand the companies’ global marketing efforts.

In August, Roche struck a couple of deals to flesh out its portfolio. The company snatched up microbiology firm GeneWeave BioSciences to boost its offerings for drug-resistant bacteria testing. It also acquired Kapa Biosystems to get its hands on the company’s next-generation sequencing products and build out its NGS portfolio.

Related Articles:
Roche scores first liquid biopsy FDA approval with Tarceva companion Dx
Roche launches home testing device for anticoagulant patients in Europe
Roche launches rapid HIV, hep C tests in Europe
Roche's M&A party rages on with Kapa Biosystems deal
Roche shells out up to $425M for superbug testing outfit

Roche - Top R&D innovators in med tech
Read more on

Suggested Articles

The FDA disclosed over 60 safety reports related to intra-aortic balloon pumps manufactured by Maquet and Datascope, following a recall this summer.

Truvian Sciences raised $27.1 million to fuel the development of its benchtop blood tester, bringing the company’s total funding to $46.3 million.

The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.